MAP2K7 and melanoma: While this concept is supported by preclinical studies [26,28,31] and mathematical modeling [32], its applications in the clinic may prove to be more difficult: in a recent randomized phase two clinical trial in melanoma patients treated with a combination of BRAF and MEK inhibitors, intermittent dosing did not improve progression-free and overall survival [33].